Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
DOI: 10.1016/s2468-1253(25)00129-3
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2468125325001293
其他信息:
出版社: Elsevier BV
作者: Silvio Danese; Jessica R Allegretti; Stefan Schreiber; Laurent Peyrin-Biroulet; Vipul Jairath; Geert D'Haens; Jarosław Kierkuś; Rupert W Leong; Andres J Yarur; Michael S Vincent; Anindita Banerjee; Deepa E Chandra; Elena Peeva; Srividya Neelakantan; Kenneth E Hung; Jacqueline M McBride; Daniela Bojic; Karen Lasch; Courtney Schiffman; Brian G Feagan

